NXSCF (Next Science) Shares Buyback Ratio %: -0.16 (As of Aug. 24, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Next Science Shares Buyback Ratio %?

Next Science NXSCF Shares Buyback Ratio % is -0.16 as of Aug. 24, 2026. The stock has 7 warning signs investors should review.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. Next Science's current shares buyback ratio was -0.16%.

Next Science Shares Buyback Ratio % Related Terms

Next Science Shares Buyback Ratio % Historical Data

* Premium members only.

The historical data trend for Next Science's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Next Science Shares Buyback Ratio % Chart

Next Science Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shares Buyback Ratio %
Get a 7-Day Free Trial -7.85 -1.94 -8.49 -35.80 -0.16

Next Science Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -35.80 0.00 -0.16 0.00

Next Science Shares Buyback Ratio % Calculation

Next Science's Shares Buyback Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Dec. 2023 ) - Shares Outstanding (EOP) (A: Dec. 2024 )) / Shares Outstanding (EOP) (A: Dec. 2023 )
=(291.695 - 292.160) / 291.695
=-0.16%

Next Science's Shares Buyback Ratio for the quarter that ended in Jun. 2025 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Dec. 2024 ) - Shares Outstanding (EOP) (A: Jun. 2025 )) / Shares Outstanding (EOP) (A: Dec. 2024 )
=(292.160 - 292.160) / 292.160
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Shares Buyback Ratio % →
What does a Shares Buyback Ratio % of -0.16 mean?
Next Science (NXSCF) has a Shares Buyback Ratio % of -0.16 as of Aug. 24, 2026. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Next Science and its competitors.
Is Next Science's Shares Buyback Ratio % too high?
Next Science's current Shares Buyback Ratio % is -0.16.
How does Next Science's Shares Buyback Ratio % compare to GCAN and PTPI?
Next Science's Shares Buyback Ratio % of -0.16 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Buyback Ratio % for a Drug Manufacturers company?
A good Shares Buyback Ratio % depends on the Drug Manufacturers industry context. However, Shares Buyback Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Buyback Ratio % mean?
A high Shares Buyback Ratio % can signal that a stock is expensive relative to its fundamentals. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Next Science and its competitors. Next Science's current Shares Buyback Ratio % is -0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Next Science stock overvalued right now?
Next Science (NXSCF) has a current Shares Buyback Ratio % of -0.16. The stock's GF Value™ is $0.26, compared to a current price of $0.00 — trading 99.6% below its estimated fair value. The current Shares Buyback Ratio % is -0.16. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Buyback Ratio % calculated?
Shares Buyback Ratio % is calculated from a company's financial statements. For Next Science (NXSCF), the current Shares Buyback Ratio % is -0.16 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Next Science Business Description

Address 264-278 George Street, Level 14, Australia Square, HWL Ebsworth, Sydney, NSW, AUS, 2000
Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with efficacy in eradicating both biofilm-based and free-floating bacteria. Its products include Bactisure, XEPERIENCE and BLASTX. The company derives revenue from North America, New Zealand, and Australia.